Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many mal...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2022-03, Vol.36 (3), p.781-789
Main Authors: Newman, Alexander M., Zaka, Masood, Zhou, Peixun, Blain, Alex E., Erhorn, Amy, Barnard, Amy, Crossland, Rachel E., Wilkinson, Sarah, Enshaei, Amir, De Zordi, Julian, Harding, Fiona, Taj, Mary, Wood, Katrina M., Televantou, Despina, Turner, Suzanne D., Burke, G. A. Amos, Harrison, Christine J., Bomken, Simon, Bacon, Chris M., Rand, Vikki
Format: Article
Language:English
Subjects:
45/22
45/23
45/61
45/77
631/67/69
692/699/1541/1990/291/1621/1915
Abnormalities
Adolescent
Burkitt's lymphoma
Cancer Research
Child
Child, Preschool
Copy number
Critical Care Medicine
Disease Progression
Female
Gene deletion
Gene Dosage
Genetic Loci
Hematology
Heterozygosity
Humans
Immunotherapy
Infant
Intensive
Internal Medicine
Loss of heterozygosity
Lymphocytes B
Lymphoma
Lymphoma, B-Cell - genetics
Lymphoma, B-Cell - pathology
Male
Medicine
Medicine & Public Health
Mutation
Non-Hodgkin's lymphoma
Oncology
Patients
Pediatrics
Risk
Risk groups
Survival
Tumor Suppressor Protein p53 - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p  
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-021-01444-6